Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Phase Ⅲ Study of Paclitaxel Polymeric Micelles for Injection Versus Physician's Choice(TPC) in Human Epidermal Growth Factor Receptor 2-negative (HER2-) Metastatic Breast Cancer (MBC) Subjects Who Have Failed at Least Two Previous Chemotherapy Regimens.

NCT06143553 is registered in ClinicalTrials.gov with Shanghai Yizhong Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06143553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06143553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Phase Ⅲ Study of Paclitaxel Polymeric Micelles for Injection Versus Physician's Choice(TPC) in Human Epidermal Growth Factor Receptor 2-negative (HER2-) Metastatic Breast Cancer (MBC) Subjects Who Have Failed at Least Two Previous Chemotherapy Regimens.
Lead sponsor
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
September 25, 2023
Completion date
December 31, 2025
Enrollment
168 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer (mbc)